List of Vaccines Companies in Belgium - 18

We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships based on the adoption of our game changing team know-how and technology platforms.

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair.

CuraVac is a clinical-stage biotech developing a new class of targeted therapeutic vaccines / immunotherapies for autoimmune diseases. Our first therapeutic vaccine is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' diease, Hashimoto's disease, Type 1 Diabetes, ...

Immunotherapy is a Bio-pharmaceutical company that develops a safe and highly effective approach for cancer treatment, focusing on Glioblastoma multiforme using its patented Gliovac/ERC1671.

Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late stage projects by using our proprietary platforms across RNA chemistry, LNP formulation and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

Exothera is a contract research, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. At Exothera and Univercells, Our mission is to make life-changing therapies available to all. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing. Company number: 0744643660 VAT: BE0744643660

Huvepharma is a fast growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications. Huvepharma is a privately owned company headquartered in Sofia, Bulgaria.

ImmuneSpec offers a cutting-edge immunopeptidomics platform designed to accelerate and enhance the identification of immunogenic peptides. Utilizing a state-of-the-art mass spectrometry (MS)-based approach, our platform provides unparalleled accuracy and depth in profiling the peptide landscape presented by MHC molecules. By enabling the precise detection and characterization of these peptides, we empower life sciences, biotechnology companies, and CROs to accelerate the development of transformative therapies, including broad-spectrum vaccines, personalized medicine, and novel immunotherapeutics. By offering a thorough and unbiased analysis of the immunopeptidome, we empower researchers to discover new targets, enhance known antigens, and detect rare, mutation-derived neoepitopes that are ideal candidates for biotherapeutics. Additionally, we identify immunogenic regions within biotherapeutics, helping to optimize their design and reduce potential immunogenicity, thereby improving safety and efficacy profiles.

The Faculty of Theology and Religious Studies, part of the Catholic University of Leuven (KU Leuven), was founded in 1432. It has played a significant role in the development and diffusion of theological thought in Europe, focusing on academic formation, research and scientific service in the field of theology and religious studies. The Faculty is nowadays composed of five research units: Biblical Studies, Systematic Theology, Theological Ethics, History of Church and Theology and Pastoral Theology. Located in the heart of Europe, the Faculty of Theology and Religious Studies is known for its international character. Students from all over the world have joined our international programmes in English, and international scholars regularly visit Leuven to attend conferences or to study at the Maurits Sabbe Library, considered as one of the best theological libraries of the world.

myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.

Ovizio Imaging Systems, founded in 2009, is a Belgian company that provides the bioprocessing industry with a unique PAT for gathering insight into their cell culture process. The Ovizio platform utilizes label-free, non-destructive, holographic microscopy to detect changes in cell morphology, which is recorded by the microscope and interpreted by AI into meaningful data. The bio-connect, a single-use disposable, allows for closed-loop travel of the cells between the bioreactor and the instrument for analysis. Some applications of interest include cell density and viability metrics, cell counting of cells on microcarriers, transduction or transfection efficiency, cell subtype differentiation, cell activation, and early stage bacterial or fungi contamination. Ovizio’s flagship instrument, the iLineF Pro, is GMP qualified and is commonly used in the cell & gene therapy industry where it is deployed in manufacturing, as well as process development.

4Clinics is a Contract Research Organization (CRO) providing Data management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with a particular expertise in vaccines, immunology, immuno-oncology and medical devices. 4Clinics serves pharmaceutical, biotechnology and medical devices companies as well as NGOs, hospitals and researchers with tailor-made services including remote biometry and medical writing platforms. 4Clinics has offices in Belgium, France and Morocco and has a global coverage. For more information, please visit www.4Clinics.com

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. PDC*line offers unique advantages: - PDC*line is a professional and universal antigen-presenting cell much more potent than conventional (myeloid) Dendritic cells; - unlike conventional autologous Dendritic Cells, PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years. - The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population. - The approach is very versatile and applicable to any cancer type. Based on a first-in-human phase Ib study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo). The company regroups a team of 42 persons led by Eric Halioua (CEO) and raised close to 61M€ in equity and loans since its foundation. March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tiered royalties on net sales in Asia.

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit.

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow. Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 with the support of the Univercells group.

Ziphius Vaccines is a biopharmaceutical company, dedicated to develop saRNA vaccines and therapeutics. Ziphius focuses on both vaccines for infectious diseases and gene supplementation therapies for rare genetic disorders. Since our founding in 2019, Ziphius has worked to develop and validate its self-amplifying RNA and LNP platforms. Currently, these platforms are being used to rapidly expand our pipeline and move forward multiple preclinical development programs towards the clinic.

The world’s leading animal health company. Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. Community Guidelines: This page is intended for learning more about how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are some guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use